Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in the Treatment of Relapsed and Refractory Multiple Myeloma:...
share announcement

Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 September 2025 | Viewed by 315

Special Issue Editors

Prof. Dr. Klaus Podar

E-Mail Website
Guest Editor
Department of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria
Interests: multiple myeloma; breast cancer; signal transduction; tumor microenvironment; angiogenesis; bone disease; targeted therapy; apoptosis
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Xavier Leleu

E-Mail Website
Guest Editor
Service d’Hematologie et Therapie Cellulaire, and Inserm CIC U1402, 86000 Poitiers, France
Interests: myeloma; drug development; treatment sequences; immunology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Despite the challenges and odds imposed by the COVID-19 pandemic, therapeutic progress continues to be made in multiple myeloma (MM). New approvals in 2020 include the CD38 monoclonal antibody (mAb) isatuximab in combination with pomalidomide and dexamethasone; the combination of daratumumab with carfilzomib and dexamethasone; and the antibody drug conjugate (ADC) belantamab-mafodotin, for the treatment of relapsed/refractory (RR)MM; and s.c. daratumumab for all lines of therapy.

The combinatorial use of IMiDs, proteasome inhibitors, and monoclonal antibodies (mAbs), cornerstones of current MM therapy, has revolutionized MM treatment strategies and significantly improved patient survival. Nevertheless, almost all MM patients who have received initial therapy eventually relapse, with responses becoming progressively shorter with each line of therapy. Continuous clinical and basic research to identify novel therapeutic targets, optimal drug combinations and their timing dependent on disease, prior treatment and patient characteristics in a cost-effective and safe manner are therefore needed.

In this issue, eminent experts in the field of MM will summarize the most recent therapeutic developments, and offer evidence-based recommendations for combinatorial treatment approaches in RRMM patients. Among other topics, current strategies to treat MM patients refractory to lenalidomide, PIs, and/or mAbs in early or late relapse; and high-risk patients will be discussed. Moreover, promising biomarkers for drug resistance, therapy response, and tolerability using gene expression and proteomic profiling, as well as FACS analysis will be summarized. In addition, authors will present data on agents whose approval is expected during the next months; and on the impact of the “next-generation” of immunotherapies, chimeric antigen receptor T cells (CAR T cells), bispecific T cell engagers (BiTEs) and ADCs, as well as vaccines, in particular.  

Prof. Dr. Klaus Podar
Prof. Dr. Xavier Leleu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myeloma relapse setting
  • drug development
  • treatment sequences
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 247 KiB  
Article
Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma
by Valérie Gennheimer, Dilara Akhoundova, Michèle Hoffmann, Barbara Jeker, Yara Banz, Ulrike Bacher and Thomas Pabst
Cancers 2025, 17(8), 1297; https://doi.org/10.3390/cancers17081297 - 11 Apr 2025
Viewed by 191
Abstract
Background: Patient management following a multidisciplinary tumor board (MTB) recommendation has become standard of care in oncology and aims to ensure optimization and personalization of patient care. To assess the impact of MTB recommendations in clinical practice, adherence to the recommended procedures needs [...] Read more.
Background: Patient management following a multidisciplinary tumor board (MTB) recommendation has become standard of care in oncology and aims to ensure optimization and personalization of patient care. To assess the impact of MTB recommendations in clinical practice, adherence to the recommended procedures needs to be evaluated. Within this retrospective case series, we examined adherence rates to recommendations formulated at multidisciplinary myeloma tumor boards (MMTB) held at our institution. Specifically, we analyzed how often recommendations involving diagnostic procedures, therapies, and enrollment into clinical trials recommended by the MMTB were implemented. In addition, factors leading to non-adherence were evaluated. Methods: We reviewed all consecutive patient cases discussed at MMTBs held at the University Hospital of Bern, Switzerland, between 1 January and 31 December 2023. Adherence was assessed by systematically comparing all available clinical records with the recommendations formulated at the MMTBs. Results: In total, 218 patients were included in the study. Of all MMTB recommendations, 86% (n = 251) of all MMTB recommendations were followed. Of these, 84% (n = 244) were followed with complete adherence and 2% (n = 7) incompletely. All cases of non-implementation of MMTB recommendations concerning diagnostics or therapy were clinically justified. The main reason for non-adherence was patient decision. Other reasons included lack of cost coverage and relevant changes in the clinical scenario, including patient’s death. In total, 36% (n = 104) of MMTB recommendations included clinical trial enrollment. However, study enrollment occurred only in 32% (n = 33) of the 104 cases. In 41% (n = 29) of the cases, justification for non-enrollment was documented in the clinical records. The most frequent reasons were patient decision, unmet inclusion criteria, delays in recruitment, lack of reimbursement, and changes in the clinical scenario. Conclusions: Our study showed an overall high level of adherence to MMTB recommendations for diagnostic procedures and therapy. However, only one third of recommendations for clinical trial enrollment were implemented, frequently due to patient decisions. Our results highlight the relevance of regular assessments of adherence rates to MTB recommendations and suggest that considering patient preferences in MTB discussions might minimize deviations. Full article
(This article belongs to the Special Issue Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond: 2nd Edition)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop